Free-text search
Articles per year:
Content Types
-
From space to the world’s first fertility app: “Physics had always been my only dream”
She was user number one. Today, more than six million women worldwide have used the fertility app Natural Cycles, which is now rapidly expanding its offering. But there was a time when particle physics was all Elina Berglund Scherwitzl could think about.
-
Long‑acting asthma drug Exdensur gains reimbursement in Sweden
A new long‑acting asthma medication has now been included in the Swedish reimbursement system following a decision by TLV, making it available to patients in Sweden with severe uncontrolled asthma.
-
Nordic partnership aims for faster cancer diagnostics – ”Minutes instead of weeks”
Stratipath of Sweden is partnering with Finland‑based Aiforia to accelerate AI‑powered cancer diagnostics.
-
Leqembi Iqlik launches as start‑dose option
The Alzheimer’s drug Leqembi, discovered by the Swedish company BioArctic and developed by Eisai, has now been launched in the United States as a subcutaneous treatment for both initiation and maintenance therapy
-
Cyberattacks surge – the medtech companies hit this year
Healthcare has long been a target for cyberattacks, resulting in operational disruption and the theft of sensitive data. This year, however, growing numbers of hackers have turned their attention to another target: medtech companies.
-
BioArctic chair: “First, you need to know where you’re going”
He has been a researcher, doctor, investor and business leader. But when Eugen Steiner explains BioArctic’s success, he keeps coming back to the same thing: its vision. Speaking to Life Science Focus, he discusses CEO recruitment, the founders’ determination and why Sweden risks falling behind in clinical research.
-
Roche bets on muscle‑preserving obesity drug in $2.3 billion deal
Roche's subsidiary Genentech is investing in a new type of medicine designed to reduce fat mass while preserving or increasing muscle mass.
-
Study: Nearly 90% of biomedical papers show signs of AI assistance
The use of AI in scientific writing may be far more widespread than previous estimates have suggested. In a new study, almost nine out of ten biomedical papers from December 2025 showed linguistic signs of AI assistance, Nature reports.
-
A single inhaler, three medicines: EU approves new asthma therapy
A triple therapy for asthma delivered in a single inhaler has been approved in the EU and will now become available to Swedish patients.
-
EU backs Lundbeck’s Cushing’s drug candidate
Danish pharmaceutical company Lundbeck has been granted orphan designation by the European Commission for its drug candidate asedebart for the treatment of endogenous Cushing’s syndrome, according to a press release.
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact. Sweden Country Manager Daniel Sandgren hopes that will remain the case – yet he also sees clouds on the horizon.“Sweden risks losing its strong position in clinical trials”, he says in an interview.
-
Upgraded outlook sends Bavarian Nordic shares higher
The Danish vaccine company Bavarian Nordic’s share price rose notably on Friday following a quarterly report showing higher‑than‑expected revenue and an upgraded outlook.
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been reported in an ongoing outbreak linked to a music festival. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.
-
Implantica secures FDA approval: “Culmination of many years of development”
Swedish-founded Implantica has received Premarket Approval (PMA) from the FDA for RefluxStop, its implant-based treatment for acid reflux.
-
Lilly launches taRNA vaccine partnership
Pharma giant Eli Lilly has entered into a collaboration with the Boston‑based biotech company Amplitude Therapeutics to develop taRNA‑based vaccine candidates against infectious diseases.
-
Isotope deal boosts Uppsala radiotherapy company
Uppsala‑based Akiram Therapeutics has signed an agreement with Germany’s ITM for the supply of lutetium‑177 to support the continued development of the company’s radiopharmaceutical therapy AKIR001.
-
Melanoma data sends Moderna shares skyrocketing
A vaccine candidate from Moderna and Merck & Co almost halved the rate of skin cancer recurrence in a late-stage trial, the two companies report. The announcement sent Moderna’s share price soaring by more than 170 per cent.
-
Coloplast delays introduction of new incontinence system
Originally scheduled for release within the financial year ending in september this year, Coloplast now expects the FDA clearence of its Intibia system no earlier than october next year.
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
CEO change at Bico – ”The timing is right”
Bioconvergence company Bico Group is promoting its Chief Commercial Officer, Anders Fogelberg, to the CEO position, while current CEO and President Maria Forss is stepping down.
-
BioArctic steps into cancer research with new collaboration
BioArctic has entered a research collaboration with the Swedish‑Japanese company Mesenkia Therapeutics, marking the company’s first step into the oncology field.
-
New FDA setback for Xspray – stock plunges
The Swedish research company Xspray Pharma has received yet another negative decision from the U.S. Food and Drug Administration (FDA), linked to the company’s Italian third‑party manufacturer.
-
Trump expected to pick Heidi Overton to lead the FDA
Donald Trump is expected to nominate Heidi Overton as the new commissioner of the US Food and Drug Administration (FDA), according to several international media outlets.
-
LEO Pharma acquires dermatology drug for 435 million USD
LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
BREAKING